Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
Status:
Completed
Trial end date:
2013-05-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis
inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients
with mesothelioma